Pharmacokinetic-pharmacodynamic modelling of behavioural responses

被引:10
|
作者
Della Paschoa, OE
Kruk, MR
Danhof, M
机构
[1] Leiden Amsterdam Ctr Drug Res, Div Pharmacol, NL-2300 RA Leiden, Netherlands
[2] Leiden Amsterdam Ctr Drug Res, Div Med Pharmacol, Ethopharmacol Grp, NL-2300 RA Leiden, Netherlands
来源
关键词
PK/PD modelling; behavioural measures; data acquisition; ethopharmacology; ultrasonic vocalizations; buspirone; concentration-effect relationship;
D O I
10.1016/S0149-7634(98)00023-2
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Drug concentrations at the site of action in studies on behavioural pharmacology, are seldom constant. Therefore, observed changes in behaviour can be due to the natural time course of behavioural processes, but equally to changes in drug concentration, and it is therefore crucial to separate the former from the latter. One solution is keeping drug concentrations constant. However, one can also exploit the variation in drug concentration caused by absorption, distribution and elimination of a drug. This is done by simultaneous measurement of drug effect and concentration, while the drug enters and leaves a biologically relevant compartment, such as blood or cerebrospinal fluid. The concept of determining concentration-effect curves in individual animals, by monitoring in parallel drug effect and changes in concentration in one single experiment, has not yet found wide application in behavioural studies. The fact that behavioural processes, like any other physiological process, change over time, may have contributed to the scarcity of pharmacokinetic-pharmacodynamic (PK/PD) studies in behavioural pharmacology. However, there are now mathematical techniques that allow PK/PD modelling even if the effect parameter changes over time or cannot be properly assessed in every instance. Here we use PK/PD modelling to characterize fear-induced ultrasonic vocalizations and the anxiolytic effect of buspirone. This approach reduces the number of animals required to assess concentration-effect relationships. More importantly, it allows the identification of differences in individual drug response over a wide range of concentrations. Consequently, we suggest that PK/PD modelling can be used as a tool to study drug-induced changes in behavioural response. An introduction in PK/PD modelling is presented. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:229 / 236
页数:8
相关论文
共 50 条
  • [41] The pharmacokinetic-pharmacodynamic modelling framework as a tool to predict drug resistance evolution
    Witzany, Christopher
    Rolff, Jens
    Regoes, Roland R.
    Igler, Claudia
    MICROBIOLOGY-SGM, 2023, 169 (07):
  • [42] Pharmacokinetic-Pharmacodynamic Modelling of Opioids in Healthy Human Volunteers. A MiniReview
    Lorenzini, Kuntheavy Ing
    Daali, Youssef
    Dayer, Pierre
    Desmeules, Jules
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2012, 110 (03) : 219 - 226
  • [43] Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers
    Csajka, C
    Buclin, T
    Fattinger, K
    Brunner, HR
    Biollaz, J
    CLINICAL PHARMACOKINETICS, 2002, 41 (02) : 137 - 152
  • [44] Integrated pharmacokinetic-pharmacodynamic modelling to evaluate antimicrobial prophylaxis in abdominal surgery
    Zelenitsky, S. A.
    Lawson, C.
    Calic, D.
    Ariano, R. E.
    Roberts, J. A.
    Lipman, J.
    Zhanel, G. G.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (10) : 2902 - 2908
  • [45] Assessment of the Potential for Displacement Interactions with Sugammadex A Pharmacokinetic-Pharmacodynamic Modelling Approach
    Zwiers, Alex
    van den Heuvel, Michiel
    Smeets, Jean
    Rutherford, Samantha
    CLINICAL DRUG INVESTIGATION, 2011, 31 (02) : 101 - 111
  • [46] Population Pharmacokinetic-Pharmacodynamic Modelling of Angiotensin Receptor Blockade in Healthy Volunteers
    Chantal Csajka
    Thierry Buclin
    Karin Fattinger
    Hans R. Brunner
    Jérôme Biollaz
    Clinical Pharmacokinetics, 2002, 41 : 137 - 152
  • [47] Pharmacokinetic-pharmacodynamic modelling of recombinant human erythropoietin in athletes - A population approach
    Gaudard, A
    Varlet-Marie, E
    Audran, M
    Gomeni, R
    Bressolle, F
    CLINICAL DRUG INVESTIGATION, 2003, 23 (03) : 167 - 179
  • [48] Utilisation of Pharmacokinetic-Pharmacodynamic Modelling and Simulation in Regulatory Decision-Making
    Jogarao V. S. Gobburu
    Patrick J. Marroum
    Clinical Pharmacokinetics, 2001, 40 : 883 - 892
  • [49] Pharmacokinetic-pharmacodynamic modelling of the antipyretic effect of two oral formulations of ibuprofen
    Trocóniz, IF
    Armenteros, S
    Planelles, MV
    Benítez, J
    Calvo, R
    Domínguez, R
    CLINICAL PHARMACOKINETICS, 2000, 38 (06) : 505 - 518
  • [50] Pharmacokinetic-pharmacodynamic modelling of zopiclone effects on human central nervous system
    Luurila, H
    Olkkola, KT
    PHARMACOLOGY & TOXICOLOGY, 1996, 78 (05): : 348 - 353